Wolfe Research Begins Coverage on Twist Bioscience (NASDAQ:TWST)

Wolfe Research started coverage on shares of Twist Bioscience (NASDAQ:TWST - Free Report) in a report published on Friday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $60.00 price objective on the stock.

Several other research firms have also issued reports on TWST. Robert W. Baird increased their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 19th. Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. Evercore ISI lifted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Scotiabank upped their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, November 19th. Finally, TD Cowen reissued a "buy" rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $51.90.

Twist Bioscience Trading Up 0.2 %

Twist Bioscience stock traded up $0.11 during trading on Friday, hitting $47.50. The company had a trading volume of 814,066 shares, compared to its average volume of 940,837. The company's 50 day simple moving average is $44.85 and its 200-day simple moving average is $46.60. Twist Bioscience has a 1-year low of $27.41 and a 1-year high of $60.90. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of -13.16 and a beta of 1.82.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,730 shares of the firm's stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the transaction, the chief executive officer now owns 495,523 shares of the company's stock, valued at $23,259,849.62. This trade represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Paula Green sold 1,057 shares of the company's stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the sale, the senior vice president now owns 121,013 shares of the company's stock, valued at $5,029,300.28. This trade represents a 0.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,787 shares of company stock worth $4,584,508 over the last three months. Insiders own 3.92% of the company's stock.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently modified their holdings of TWST. Principal Financial Group Inc. lifted its holdings in Twist Bioscience by 210.2% in the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company's stock valued at $6,057,000 after acquiring an additional 83,287 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Twist Bioscience by 215.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock valued at $1,324,000 after purchasing an additional 20,035 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Twist Bioscience in the third quarter valued at about $599,000. Charles Schwab Investment Management Inc. boosted its holdings in Twist Bioscience by 4.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company's stock worth $23,717,000 after buying an additional 24,582 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock worth $1,718,000 after buying an additional 21,357 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.